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[s1371 Salm-Net: Investigation of international 
outbreaks of salmonellosis infection 
I.S.T. Fisher', O.N. Bill', C.L.R. Badett', B. Rowe'. 'PHLS 
Communicable Disease Surveillance Centre, London, UK, 'PHLS 
Central Publit Health hboratory, London, UK 
Objectives: To identify international outbreaks of salmonellosis and 
provide the opportunity for public health measures to be imple- 
mented. 
Method: An international network of microbiologists and epi- 
demiologists with responsibility for salmonella surveillance has been 
created as a response to the rehation of trade barriers and modern 
production practices. Multi-national distribution of products gve 
rise to the opportunity for illness to occur far b m  its source and 
a network that i s  able to exchange information rapidly can react 
effectively to an international outbreak of illness. 
Results: Sevenl international outbreaks of gastro-intestinal dis- 
ease have occurred during the time that the Salm-Net network 
has been in existence. The international extent of these has been 
identified because the network has been in place and public health 
intervention has been implemented as a result of the rapid exchange 
of information. 
Conclusion: International surveillance networks provide an 
added value to national schemes and have a c r u d  role in rapid 
case finding during outbreaks. 
IS138 I Surveillance of CreutzfeldtJacob Disease in 
Europe 
L. Chambaud. L 
No abstract available. 
Surveillance of Entemhaemom/mgic E. co/i 
(€H€Cl infection and Haemolytic Uraemic 
Syndrome (HUS) in Europe: Similar Problems - 
Similar Solutions? 
Members of the European Programme of Intervention 
Epidemiology Training (EPET), A. Ammon. Robert Koch-Institut, 
Berlin, Germany 
Objectives: To describe and compare the surveillance of E H E C  
infection and HUS in Europe in terms of 
(a) the case definitions used; 
(b) number of reported cases per year with EHEC infection or 
(c) presence of Merent s t r a i n s .  
To present a synthesis of recently investigated outbreaks in Europe. 
MethoddResults: Results of a questionnaire given to all Euro- 
pean countries re- surveillance of E H E C  and HUS will be 
presented. 
HUS; 
1 S140 1 Epidemiology of Cryptospotidiosis and 
Microsporidiosis: What Do We Know in Europe? 
R. Weber. C H  
No abstract available. 
New quinolones 
(s14T] Overview of fluoroquinolone development 
E. Rubinstein. Infernus Diseares Unit, Sheba Medical Centre, El Aviv 
University school $Medicine, El Hashomer, Israel 
Recent microbiological developments, in particular an increase in 
penicillm and macrolide resistance of Streptorocrus pneumoniae, the 
increase in resistance of Enterobacteriaceae to amikacin, the world- 
wide spread of organisms that are B-lactamase producing and this 
resistant to p-lactam antibiotics, including strains that became pro- 
ducers of, the progressive spread of methxillin-resistant Sraphylo- 
cow areus (MRSA), the increase in Shigella strains resistant to 
trimethoprim-sulfamethoxazole, the spread of multiply-drug resis- 
tant Salmonella typhi, and the treatment of infections caused by 
these pathogens. Concomitantly, the expanded safe use of the flu- 
oroquinolones in pematrics and the development of newer fluoro- 
quinolones with pronounced Gram-positive activity have broadened 
the indication list of the fluoroquinolones. Indeed most newer flu- 
oroquinolones have Gram-positive activity to a lesser or a greater 
extend and have been successfdly used in the treatment of res- 
piratory tract infections skin and soft tissue infections caused by 
Gram-positive cocci. Trodoxacin, sparfloxacin, chafioxacin, lev- 
ofloxacin SFC 222, DU-6859a, Bay 12-8039, grepafloxacin, T-3762 
and other fluoroquinolones have been clinically tested, and in ini- 
hal studies found to have clinical potenhal. Some of the fluoro- 
quinolones have, in addition, anti-anaerobic activity, which expands 
their uses. Ciprofloxacin and trovafloxacin have undergone trials in 
children and found to be associated with an acceptable rate of ad- 
verse events. Fluoroquinolones have also been recently used in the 
prophylaxis and therapy of febrile neutropenia, allowing home ther- 
apy of such patients. However, s t r a i n s  resistant to fluoroquinolones 
because ofgyrA mutations, the combination ofgyrA andgyL4 muta- 
tions associated with rapid spread of fluoroquinolones resistant strains 
threaten the future of these antibiotics. The key to the continuous 
success of these agents is dependent on successful development of 
new agents coupled with sensible use of the present agents. 
I S142 Quinolones in Community-acquired Respiratory 
J. Garau. Department $Medicine, Hospital Mhtua de T ~ ~ ~ s s Q .  
Barcelona, Spain 
The main factors in the selection of first- and second-line antibacte- 
rial agents in the management of patients with community-acquired 
respiratory tract infections include spectrum of activity against com- 
mon respiratory tract infections, blood and tissue pharmacokinet- 
ics, efficacy studies, incidence of adverse events, and dosing regi- 
mens. In the last 10-15 years, a gradual change in the antibacterial 
susceptibility of common pathogens has taken place. Penicillin re- 
sistance has emerged among pneumococci, as well as p-lactamase 
production among Haemophilus iny'luenzae and Moraxella catanalis 
being prevalent in some areas of the world. As a result, the ac- 
tivity of traditionally-used antimicrobials for respiratory infections 
has been compromised. The current limitations of &lactam and 
macrolide antibacted agents have led to a resurgence of interest 
in the use of other classes of antimicrobials in their management. 
The currently-available fluoroquinolones have been used against se- 
lected respiratory mfections with some success, but there are con- 
cerns about their efficacy against dections caused by only mod- 
erately-susceptible microorganisms, in particular pneumococci. The 
development of a number of new fluoroquinolones with enhanced 
Gram-positive activity has generated a new interests. Preliminary ex- 
perience indicates that they are effecave agents in respiratory mct 
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